The clinical trial, sponsored by Abundance & Health Limited and LivOn Laboratories Inc., was a double-blind, randomised, placebo-controlled study conducted between August and November 2014 by Princeton Consumer Research. The study aimed to evaluate the anti-aging effects of varying dosages of Altrient C compared to a placebo, focusing on improvements in skin firmness and reduction of fine lines and wrinkles.

The study involved 45 healthy volunteers with self-assessed aging, non-firm skin to assess the efficacy of different treatment dosages of Altrient Liposomal Vitamin C.

Participants were divided into three groups,
Group A: 1 sachet of Altrient C per day (1000mg liposomal sodium ascorbate)
Group B: a placebo
Group C: 3 sachets of Altrient C per day (3000mg liposomal sodium ascorbate)

Assessments were made using cutometry and profilometry at the beginning of the study, then at weeks 4, 8, 12, and 16 to measure changes in skin viscoelasticity and appearance of fine lines and wrinkles.

The cutometer assessments focused on measuring the skin's viscoelastic properties, essentially its firmness and elasticity. These properties are indicative of the skin's ability to resist deformation and return to its original state after being stretched or compressed. The profilometry assessments were aimed at quantifying the skin's texture, specifically analysing the depth and number of fine lines and wrinkles, which are common indicators of skin aging.

The clinical trial demonstrates that Altrient C, even at standard dosages, significantly improves skin firmness and reduces the appearance of fine lines and wrinkles. These findings highlight the importance of Altrient C for supporting an anti-aging skincare protocol and underscores the importance of continued research in this area to fully understand the mechanisms through which vitamin C contributes to collagen production, prevention of free-radical damage and overall optimised health and wellbeing.